PARABDRUGS Intraday Analysis...

PARABDRUGS Share Price

Open 3.75 Change Price %
High 4.00 1 Day -0.05 -1.30
Low 3.70 1 Week -0.10 -2.56
Close 3.80 1 Month -0.70 -15.56
Volume 16999 1 Year -2.60 -40.62
52 Week High 9.55
52 Week Low 3.55
PARABDRUGS Important Levels
Resistance 2 4.08
Resistance 1 3.96
Pivot 3.83
Support 1 3.64
Support 2 3.52
NSE INDIA Most Active Stocks
UVSL 0.10 0.00%
ADANIPOWER 19.80 2.59%
IDBI 57.30 2.05%
GMRINFRA 17.80 -1.11%
RCOM 13.00 -3.70%
JPASSOCIAT 15.50 -4.32%
ADANIENT 131.65 5.91%
FORTIS 147.80 3.94%
JINDALSTEL 206.10 -5.85%
SUZLON 7.40 -1.33%
More..
NSE INDIA Top Gainers Stocks
RSSOFTWARE 45.65 19.97%
BHAGYANGR 49.20 15.22%
BILENERGY 0.50 11.11%
OILCOUNTUB 20.85 10.90%
SOLARA 150.25 9.99%
ARIHANTSUP 69.75 9.93%
SUPREMETEX 0.60 9.09%
AGARIND 293.95 8.67%
ONWARDTEC 78.25 8.61%
HINDSYNTEX 5.75 8.49%
More..
NSE INDIA Top Losers Stocks
KSERASERA 0.15 -25.00%
RAJRAYON 0.20 -20.00%
SPYL 0.25 -16.67%
MVL 0.25 -16.67%
MVL 0.25 -16.67%
NDGL 1217.40 -14.74%
PVR 1211.20 -13.24%
PVR 1211.20 -13.24%
TGBHOTELS 23.95 -11.79%
JIKIND 0.45 -10.00%
More..

Parabolic Drugs Limited (NSE: PARABDRUGS)

PARABDRUGS Technical Analysis 5
As on 13th Jul 2018 PARABDRUGS Share Price closed @ 3.80 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 6.41 & Strong Sell for SHORT-TERM with Stoploss of 6.22 we also expect STOCK to react on Following IMPORTANT LEVELS.
PARABDRUGS Target for July
1st Target up-side 4.81
2nd Target up-side 5.51
3rd Target up-side 6.22
1st Target down-side 2.79
2nd Target down-side 2.09
3rd Target down-side 1.38
PARABDRUGS Synopsis Technicals View
50 Day EMA Close is Below EMA 50 (Short Term)
Bearish
100 Day EMA Close is Below EMA 100 (Mid Term) Bearish
200 Day EMA Close is Below EMA 200 (Long Term) Bearish
MACD (12 26 9) MACD Line is Grater Then SIGNAL Line Bullish
RSI (14) RSI is 39.79 Sideways
MFI (14) MFI is 40.18 Sideways
CCI (20) CCI is -70.06 Sideways
WILLIAM %R (14) William %R is -70.59 Sideways
ADX (14) ADX is Above 20 & +DI is Below -DI Down Trend
PSAR Stoploss For Long Buy 3.68
10 Day Avg Volume Traded 85.73 % More then 10 Day Average Volume
PARABDRUGS Other Details
Segment BE
Market Capital 0.00
Sector Pharmaceuticals
Industry
Offical website
PARABDRUGS Address
PARABDRUGS
N/A
PARABDRUGS Latest News
Balwan Bansal quits Parabolic Drugs Ltd   Equity Bulls   - 16th Feb 15
How BALLET PUMPS could leave you limping or even missing a toe: Soaring ...   Daily Mail   - 09th Feb 15
Richard Branson should give up on space tourism says rocket scientist   Daily Mail   - 02nd Nov 14
Catalysts on the Horizon for Companies Developing NAFLD and NASH Drugs   MarketWatch   - 26th Jun 14
Parabolic Drugs updates on CDR application   Moneycontrol.com   - 03rd Apr 13
Parabolic Drugs Ltd's CDR Application approved   Equity Bulls   - 02nd Apr 13
Parabolic Drugs a good bet for long-term play   Economic Times   - 03rd Jan 12
Mr. Vineet Gupta, Executive Director, Parabolic Drugs Ltd.   India Infoline.com   - 28th Mar 11
Parabolic Drugs IPO fully subscribed   Moneycontrol.com   - 17th Jun 10
Parabolic Drugs has a limited product   Moneylife Personal Finance Magazine   - 11th Jun 10
Interactive Technical Analysis Chart Parabolic Drugs Limited ( PARABDRUGS NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Parabolic Drugs Limited
PARABDRUGS Business Profile
Parabolic Drugs is in the Pharmaceuticals sector. The current market capitalisation stands at Rs 27.17 crore.The company has reported a standalone sales of Rs 117.12 crore and a Net Loss of Rs 22.32 crore for the quarter ended Sep 2013.The company management includes Pranav Gupta - Chairman & Managing Director, Vineet Gupta - Whole Time Director, Balbir Singh Bhasin - Director, Arun Mathur - Director, Nikhil Goel - Director, Balwan Bansal - Director. It is listed on the BSE with a BSE Code of 533211 and the NSE with an NSE Code of PARABDRUGS.Its Registered office is at S.C.O 99-100, Top Floor,,Sector 17 - B Chandigarh,Chandigarh - 160017.Their Registrars are Link Intime India Pvt. Ltd.